Genpharmasec Limited conducted its separate meeting of independent directors on March 24, 2026, fulfilling its regulatory obligations under the Companies Act, 2013 and SEBI listing regulations. The meeting represents a key governance milestone for the pharmaceutical company as it ensures compliance with mandatory corporate governance requirements.

Meeting Details and Compliance Framework

The independent directors' meeting was held in accordance with Schedule IV of the Companies Act, 2013 and Regulation 25(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The session was conducted on Tuesday, March 24, 2026, demonstrating the company's commitment to maintaining robust governance standards.

Key Agenda Items and Performance Review

The independent directors addressed three critical governance areas during their deliberations. The meeting focused on comprehensive performance assessments across multiple organizational levels, ensuring thorough evaluation of the company's leadership structure.

The directors undertook the following key activities:

• Board Performance Review: Evaluated the performance of non-independent directors and assessed the board's overall effectiveness
• Chairperson Assessment: Reviewed the chairperson's performance while incorporating feedback from both executive and non-executive directors
• Information Flow Analysis: Assessed the quality, quantity, and timeliness of information exchange between management and the board of directors

Governance and Information Management

The meeting emphasized the critical importance of effective information flow within the organization. The independent directors specifically evaluated whether the management provides adequate, timely, and quality information to enable the board to perform its duties effectively and reasonably.

This assessment ensures that board members have access to necessary information for informed decision-making and strategic oversight. The evaluation process strengthens the overall governance framework by identifying potential gaps in communication channels between management and the board.

Regulatory Filing and Documentation

Genpharmasec Limited promptly communicated the meeting outcome to BSE Limited through an official filing. The documentation was signed by Mr. Siddhesh Shende, Independent Director with DIN: 09629926, ensuring proper authentication and compliance with exchange requirements.

The company's proactive approach to regulatory communication demonstrates its commitment to transparency and adherence to listing obligations. This separate meeting of independent directors represents an essential component of the company's annual governance cycle, reinforcing stakeholder confidence in its corporate governance practices.

Genpharmasec Limited announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating significant growth in standalone operations while navigating integration challenges in its consolidated business. The Board of Directors approved these results at their meeting held on February 09, 2026, pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting and Regulatory Compliance

The company formally communicated the outcome of its Board meeting to BSE Limited, confirming that the meeting commenced at 04:00 p.m. and concluded at 04:40 p.m. on February 09, 2026. The Board considered and approved the unaudited standalone and consolidated financial results along with the limited review report of the auditor for the quarter ended December 31, 2025.

Standalone Financial Performance

The company delivered exceptional standalone revenue growth, with revenue from operations reaching Rs. 3,600.83 lakhs in Q3FY26, representing a substantial increase of 332.00% compared to Rs. 833.56 lakhs in Q3FY25. For the nine-month period ended December 31, 2025, standalone revenue grew to Rs. 7,968.51 lakhs from Rs. 1,940.80 lakhs in the corresponding period of the previous year.

Despite strong revenue performance, standalone profit before tax declined to Rs. 48.77 lakhs from Rs. 171.44 lakhs in the previous year quarter. Net profit for the quarter stood at Rs. 75.64 lakhs compared to Rs. 110.50 lakhs in Q3FY25, primarily due to higher cost of materials consumed which increased to Rs. 3,384.96 lakhs from Rs. 822.19 lakhs.

Consolidated Operations Show Integration Challenges

Consolidated financial results reflected the impact of recent acquisitions and business integration efforts. Consolidated revenue from operations grew to Rs. 3,982.81 lakhs in Q3FY26 from Rs. 848.41 lakhs in Q3FY25. However, the company reported a consolidated loss before tax of Rs. 133.22 lakhs compared to a profit of Rs. 126.90 lakhs in the corresponding quarter of the previous year.

Segment-wise Performance Analysis

The company operates across three primary segments: Pharmaceuticals, Laboratory Testing, and Manufacturing & Processing. The pharmaceuticals segment generated revenue of Rs. 3,681.83 lakhs in Q3FY26, while the newly added Manufacturing & Processing segment contributed Rs. 278.79 lakhs. However, this segment reported a loss of Rs. 123.95 lakhs, indicating integration challenges following the Derren Healthcare acquisition.

Key Corporate Developments

During the year ended March 31, 2024, the company entered into agreements with Derren Healthcare Private Limited for acquiring a 70% stake. The acquisition was completed on July 25, 2025, making Derren Healthcare a subsidiary. This acquisition has contributed to the Manufacturing & Processing segment but is currently showing operational losses as integration efforts continue.

The company also implemented significant accounting policy changes, reclassifying certain equity shares from inventories to financial investments. These instruments are now measured at fair value through other comprehensive income (FVOCI), resulting in a decrease in inventories of Rs. 89.32 lakhs with a net impact on total comprehensive income of Rs. (19.67) lakhs.

Earnings Per Share and Capital Structure

Standalone basic and diluted earnings per share stood at Rs. 0.01 for Q3FY26 compared to Rs. 0.02 in Q3FY25. On a consolidated basis, the company reported a loss per share of Rs. (0.02) for the quarter. The paid-up equity share capital remained stable at Rs. 5,537.20 lakhs with a face value of Re. 1 per share.

Regulatory and Compliance Updates

The company noted the implementation of New Labour Codes effective from November 21, 2025, which consolidated 29 existing labour legislations into four codes. Management's assessment, including actuarial valuation, indicated no material incremental impact on gratuity obligations, and no adjustments were made to the financial results for the quarter.